摘要
Abstract
Objective:To evaluate the effect and side-effect of Nedaplatin and cisplatin(DDP) in concur rent chemoradiotherapy (CCRT) treatment of cervical cancer. Methods:68 first treated cervical cancer patients were randomly classified to two groups, Nedaplatin group and DDP group. Radiotherapy in two groups was the same, which used external radiation with 3 dimensional conformal radiation therapy technic (3DCRT) and high dose rate intracavitary therapy. The radiation and CCRT started at the same time, and the frequence was once every week for 6 weeks. The Nedaplatin group was given Nedaplatin 40 mg/m2, ivgtt, weekly, for6 weeks. DDP group was given DDP 40 mg/m2, ivgtt, weekly, for 6 weeks. The effects and side-effects of treatment in two groups were observed and compared. Results;All patients had finished CCRT treatment and followed up. Overall survival rate at 1,2,3 years in Nedaplatin group and DDP group were 91. 2% ,82. 4% ,76. 5% and 85. 3% ,73. 5% ,70.6% (P ＞ 0. 05) respectively. Disease free survival rate at 1,2,3 years in Nedaplatin group and DDP group were 88. 2% ,73.5% ,64. 7% and 82. 3% ,64.7%, 61.8% (P＞0. 05) respectively. Incidence of grand I and grand K anorexia was 17. 6% (6/34) and 35. 3%(12/34)(P＜0. 05), incidence of grade I and U nausea and vomiting reaction were 20.6% (7/34) and 55. 9% (19/34) (P ＜ 0. 05). The descending percentage of hemoglobin in two groups were 17.6% (6/ 34) and 35. 3%(12/34) respectively (P＜0. 05). Incidence of grand I and grand TJ nephrotoxicity were 5. 9%(2/34) and 32. 3% (11/34) (P＜0. 05). Incidence of grand I and grand U thrombocytopenia were 38. 2% (13/34) and 17. 6% (6/34) (P ＜ 0. 05). Conclusions: Nedaplatin can be used in CCRT in cervical cancer. The side effects of Nedaplatin including gastrointestinal reaction and renal toxicity are lower than that of cisplatin. The total survival rate and disease free survival rate are the same, but tends to elevate in Nedaplatin, which is worth to give further study by enlarging the sample size.关键词
宫颈癌/同步放化疗/顺铂/奈达铂Key words
Cervical cancer/Concurrent chemoradiotherapy/Cisplatin/Nedaplatin分类
医药卫生
